| A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma (NCT00000763) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant (NCT00001019) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection (NCT00006630) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effects of Illnesses on HIV Levels in the Body (NCT00000900) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC) (NCT00001009) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma (NCT00005668) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3 (NCT00000844) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men (NCT00063804) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance (NCT00046033) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients (NCT00001085) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients (NCT00061256) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy (NCT00000850) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| HIV Educational Programs for Villagers of Funan County or Yingzhou District, Anhui Province, China (NCT00068991) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease (NCT00000719) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda (NCT01549470) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults (NCT01964937) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection (NCT00038272) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase I Trial of an Intervention to Increase Condom Use by HIV-Discordant Couples (NCT00000928) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 (NCT00000771) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts (NCT00000908) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs (NCT00050063) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease (NCT00000938) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection (NCT00000959) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT (NCT00001032) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effects of Zidovudine on the Blood of HIV-Infected Patients (NCT00000965) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus (NCT00006643) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis (NCT00000950) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women (NCT00000839) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults (NCT00026611) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only) (NCT00000958) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities (NCT00015691) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients (NCT00001023) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women (NCT00000862) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease (NCT00000805) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of HIV in Newly Infected Individuals (NCT00000930) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms (NCT00000707) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Two Methods of Determining When to Begin or Change Anti-HIV Treatment (NCT00001069) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of the Interaction Between Acetaminophen and Zidovudine (NCT00000731) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers (NCT00039975) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B (NCT00007332) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza (NCT01063933) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Long Term Follow-Up of HIV Infected Patients Who Have Previously Participated in HIV Clinical Trials (NCT00183287) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002 (NCT00000682) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection (NCT00006154) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery (NCT00540605) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy (NCT00000722) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs (NCT00001087) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment (NCT00006152) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome (NCT00000627) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants (NCT00000829) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Zidovudine in HIV-Infected Patients With Liver Disease (NCT00001001) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers (NCT00000690) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients (NCT00001022) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients (NCT00000912) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs (NCT00004855) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| TG4040 in Patients With Chronic HCV (NCT00449124) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns (NCT00006396) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| High Dose Influenza in Immunosuppressed Subjects (NCT00766285) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3. (NCT00000818) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru (NCT00023582) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis (NCT00023218) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection (NCT00000760) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients (NCT00001057) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults (NCT00001052) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Urinary Schistosomiasis Infection (NCT00138450) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3 (NCT00001064) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir (NCT00000668) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection (NCT00000823) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Collection of Blood Samples From SMART Study Participants for Future Genetic Studies (NCT00377169) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Azithromycin Combination Therapy for Malaria (NCT00299208) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Acceptability of PRO 2000 Vaginal Gel in HIV Uninfected Women in India (NCT00081640) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine (NCT00722774) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir (NCT00000697) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS (NCT00001058) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals. (NCT00000641) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| SARS Coronavirus Vaccine (SARS-CoV) (NCT00533741) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy (NCT00008866) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa (NCT00498056) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants (NCT00001107) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Blood Levels of Abacavir After One Dose in HIV-Infected Children and Adolescents (NCT00011479) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone (NCT00000870) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children (NCT00001106) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults (NCT00415649) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (NCT00001003) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults (NCT00000877) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC) (NCT00001006) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection (NCT00000852) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women (NCT00125983) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome (NCT00000726) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS (NCT00000674) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59 (NCT00000632) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons (NCT00001060) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children (NCT00006325) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole (NCT00001065) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of HIV Levels During Pregnancy and After Childbirth (NCT00041964) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection (NCT00125099) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients (NCT00006617) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS (NCT00000989) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems (NCT00006066) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections (NCT00001035) | National Institute of Allergy and Infectious Diseases (NIAID) | |